Sorrento Subsidiary, SCILEX Pharmaceuticals, Announces Key Endpoints Met in the European Union Pivotal Bioequivalence Clinical Study for Its Lead Product, ZTlido(TM)

Stock Information for Sorrento Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.